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LETTER TO THE EDITOR
Modified protocol of omalizumab 
treatment to prevent carboplatin-induced drug 
hypersensitivity reactions: a case study
Hanneke N. G. Oude Elberink1,2,3, Mathilde Jalving1,2,3, Hilda Dijkstra1,2,3 and Annick A. J. M. van de Ven1,2,3* 
Abstract 
Carboplatin administration can usually be safely continued via a so-called desensitisation protocol when hypersensi-
tivity reactions arise. Severe break-through reactions that occur early during desensitisation are likely to be IgE-medi-
ated; in that case, addition of omalizumab premedication should be strongly considered.
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To the editor
Platinum-based chemotherapy is the cornerstone in the 
treatment of various solid tumours, including gynaeco-
logic malignancies. The incidence of drug hypersensitiv-
ity reactions (DHRs) is high; up to 12% for carboplatin in 
gynaecological tumours [1]. The pathogenesis of platin-
related DHRs may vary but for carboplatin, IgE-specific 
basophil activation has been demonstrated [2].
Fortunately, patients with a DHR to carboplatin can 
generally still be safely treated with carboplatin using a 
desensitisation protocol [3]. Protocols rely on two main 
principles, namely gradually increasing the dose of drug 
and using a premedication consisting of a combination 
of H1-, H2-antihistamines, corticosteroids and in some 
cases a leukotriene antagonist [3]. This method is suc-
cessful for most patients; however, some still suffer from 
symptoms despite intense pre-treatment and extra anti-
allergy medication during the desensitisation procedure. 
We describe a patient who developed a systemic aller-
gic reaction at the first step (1  mg carboplatin/hour) of 
the desensitisation schedule on two separate occasions. 
Carboplatin treatment could, however, be successfully 
continued after pre-treatment with omalizumab and no 
further adverse events occurred.
The case concerns a now 57-year-old woman diagnosed 
with stage III ovarian cancer of the endometrioid type 
in 2008 (Table 1). In 2014, she had a platinum-sensitive 
relapse without rational surgical options and palliative 
chemotherapy with carboplatin/paclitaxel was initiated. 
During the second cycle, she developed an allergic reac-
tion consisting of patchy erythema, coughing, throat 
and chest discomfort. The chemotherapy was stopped 
and referral to an allergologist followed. Carboplatin 
hypersensitivity was diagnosed based on the clinical 
presentation in combination with skin tests positive for 
carboplatin (Table 2). Three subsequent cycles of carbo-
platin were given according to a 10-step desensitisation 
schedule and were uneventful. (Figure 1a).
The desensitisation procedure was successfully 
repeated with a relapse 3  years later. In 2018, carbopl-
atin monotherapy was initiated due to a third sympto-
matic platinum-sensitive relapse. During the first cycle, 
an allergic reaction occurred at the last desensitisation 
step (Fig.  1b). The reaction consisted of flushing, pru-
ritus and erythema of the face and chest. The carbopl-
atin infused was stopped and intravenous clemastine 
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Table 1 Summary of clinical events and treatment over time
Year Event Surgical debulking Adjuvant chemotherapy Allergology
2008 Stage III ovarian cancer of the endometri-
oid type
Yes 6 Cycles of carboplatin and paclitaxel
2009
2010 Disease relapse Yes No
2011
2012
2013 Disease relapse Yes No
2014 Symptomatic platinum-sensitive disease 
relapse
Not possible 2 Cycles of carboplatin/paclitaxel
Cycle 3 omitted
Cycle 4–6 according to 10-step desensiti-
sation schedule
Cycle 2: allergic reaction
Skin tests positive for carbopl-
atin, negative for paclitaxel
2015
2016
2017 Symptomatic platinum-sensitive disease 
relapse
No 6 Cycles of carboplatin/paclitaxel accord-
ing to 10-step desensitisation schedule
Skin tests positive for carboplatin
2018 Symptomatic platinum-sensitive disease 
relapse
No 6 Cycles of carboplatin monotherapy 
according to 10-step desensitisation 
schedule with additional omalizumab 
for cycle 4–6
Cycle 1: flushing, pruritus and 
erythema of the face and chest
Cycle 2 + 3: Anaphylaxis
Skin tests positive for carboplatin 
(negative for cisplatin)
Cycle 4–6: Uneventful
Skin tests persistently positive
2019 Symptomatic platinum-sensitive disease 
relapse
No 6 Cycles of carboplatin monotherapy 
according to 10-step desensitisation 
schedule with additional omalizumab
No events
Table 2 Diagnostic testing in suspected carboplatin allergy
Overview of intracutaneous testing for carboplatin and other chemotherapeutics. Positive results are shown in italics. Diameter = average of the length and width of 
the wheal, read 15–20 min after intracutaneous injection of the drug
N/A not assessed
* Skin tests were performed 8 weeks after the last omalizumab injection
Time after initial diagnosis (years) 6.5 9.5 11 11.2
Status Prior to 2nd series of 
carboplatin/pacli-
taxel
Prior to 3rd series of 
carboplatin/pacli-
taxel
After 3 cycles carboplatin 
monotherapy (4th series), 0x 
omalizumab
After 6 cycles carboplatin 
(4th series) and 4x omali-
zumab*
Saline, diameter (mm) 0 0 0 0
Histamine, diameter (mm) 9.5 4 7.5 6
Drugs tested: diameter of wheal in mm
 Carboplatin 0.01 mg/ml 8.5 0 6 0
 Carboplatin 0.1 mg/ml N/A 0 7 6.5
 Carboplatin 1 mg/ml N/A 4.5 7.5 5.5
 Paclitaxel 0.001 mg/ml 0 N/A N/A N/A
 Paclitaxel 0.01 mg/ml 0 N/A N/A N/A
 Paclitaxel 0.1 mg/ml 0 N/A N/A N/A
 Paclitaxel 1 mg/ml 0 N/A N/A N/A
 Cisplatin 0.01 mg/ml N/A N/A 0 0
 Cisplatin 0.1 mg/ml N/A N/A 0 0
 Cisplatin 1 mg/ml N/A N/A 0 0
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within minutes. The desensitisation was successfully 
continued at the penultimate infusion rate. 3 weeks later 
she experienced a more severe reaction moments after 
commencing the first infusion step, despite pre-treat-
ment with H1/H2-antihistamines and dexamethasone. 
She had symptoms of flushing, hypotension, dyspnoea 
Total dose (mg) 726 Concentraon (mg/ml) Total per soluon 
(mg) 
Soluon A 100 ml 0.5 50 
Soluon B 100ml 0.726 72.6 
Soluon C 150ml 4.84 726 
  








1 A 2 15 0.250 0.250 
2 A 5 15 0.625 0.875 
3 A 10 15 1.250 2.125 
4 A 20 15 2.500 4.625 
5 B 20 15 3.630 8.255 
6 B 40 15 7.260 15.515 
7 C 20 15 24.2 39.7 
8 C 40 15 48.4 88.1 
9 C 80 15 96.8 184.9 
10 C 100 67 541.1 726.0 
a 
b 
Fig. 1 Management of carboplatin allergy. a 10-step desensitisation schedule for carboplatin. Cumulative dose as administered in the 6th and last 
cycle of the course. b Overview of carboplatin and omalizumab administration in relation to the adverse allergic reactions
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with chest discomfort, throat tightness and abdominal 
discomfort. Additional administration of clemastine, 
ranitidine and dexamethasone had insufficient effect and 
0.5  mg of intramuscular epinephrine was required to 
relieve symptoms. There was no alternative explanation 
for this reaction, i.e. no co-factors such as concurrent 
infection, recent exercise or use of novel medications. 
After administration of the abovementioned medication, 
the desensitisation could be continued according to pro-
tocol without further additional medication or adverse 
events. During administration of the third cycle, despite 
optimizing premedication (20  mg dexamethasone i.v., 
50 mg ranitidine i.v., 2 mg clemastine i.v. and 10 mg mon-
telukast orally, all ≥ 1 h prior to the first infusion), a simi-
lar anaphylactic reaction occurred at the first infusion 
step. Intramuscular epinephrine halted the allergic reac-
tion and again, the desensitisation could be completed 
without other events.
Since further dilution of the carboplatin to allow an 
even slower desensitisation was not possible (in accord-
ance to the SmPC of Carboplatin), other potential solu-
tions were explored. Ojaimi et al. [4] described a patient 
who failed their 2-day and subsequently 4-day desen-
sitisation protocol for carboplatin. After 3 fortnightly 
doses of 300  mg of omalizumab, a monoclonal anti-IgE 
antibody, carboplatin was successfully administered over 
4 days.
We opted to aim to reduce the burden of anti-carbo-
platin IgE-antibodies by administering omalizumab. 
Our patient received one dose of omalizumab 300  mg 
2 weeks before the 4th cycle of carboplatin was adminis-
tered, and continued fortnightly (Fig. 1b). The following 
three administrations of carboplatin occurred without 
any side effects and no adaptations to the desensitisation 
protocol were required. Omalizumab was well tolerated. 
She had a good clinical and partial radiological response 
to the chemotherapy with 73% decreased CA-125 titres 
and commenced maintenance treatment with niraparib 
6  weeks after the last cycle of chemotherapy. Unfortu-
nately, she relapsed within 6  months and carboplatin 
monotherapy was reinitiated. The anti-allergy premedi-
cation regimen included omalizumab 300  mg every 
14 days (first injection was given 11 days prior to the first 
cycle) and the desensitisation procedure was carried out 
uneventfully.
We here describe the successful addition of omali-
zumab to the conventional anti-allergic medication in a 
patient with severe break-through allergic reactions to 
carboplatin despite an optimized desensitisation sched-
ule. To our knowledge, this is the second time omali-
zumab has been used as an adjuvant during carboplatin 
desensitisation. Ojaimi and colleagues added omali-
zumab to a more conservative desensitisation protocol. 
Our results confirm their findings and suggest that one 
dose of omalizumab prior to the start of desensitisation 
may already be sufficient, thereby minimizing treat-
ment delay and enabling desensitisation procedures to 
be kept at the regular time schedule of 3.5 h.
There is limited but growing experience using omali-
zumab for desensitisation of DHR; case-reports or small 
case series describe positive results for aspirin [5], insulin 
[6], Elosulfase A, [7] and recently oxaliplatin [8]. Careful 
selection of patients remains pivotal and sufficient knowl-
edge regarding the underlying pathogenic mechanism of 
the allergic reaction is essential. Non-IgE-mediated reac-
tions are less likely to fully respond to this therapy. Con-
sequently, the mechanism of hypersensitivity reactions 
should ideally be substantiated by diagnostics in order to 
identify those patients that might benefit from the addi-
tion of omalizumab. Carboplatin-induced DHR are IgE-
mediated, as specific anti-carboplatin IgE antibodies can 
be detected in patients with DHR to carboplatin [9]. Iwa-
moto et al. nicely demonstrated in vitro an IgE-depend-
ent mechanism in patients with carboplatin DHR [2]. 
The carboplatin reactivity was transferable when plasma 
of these patients was added to healthy control basophils, 
but could be almost completely blocked when cells were 
pre-treated with omalizumab.
For our patient, measurement of anti-carboplatin 
IgE was not available and a basophil activation test was 
unsuccessful probably due to the presence of low lev-
els of omalizumab in the sample. Skin tests however 
repeatedly showed reactivity to carboplatin, which sup-
ports the presence of an IgE-mediated DHR.
Taken together, for patients with continued allergic 
reactions of established or strongly suspected IgE-medi-
ated origin despite a desensitisation schedule including 
conventional anti-allergic medication, we recommend 
additional pre-treatment with one dose of omalizumab 
1–3 weeks prior to each cycle of chemotherapy.
In conclusion, omalizumab can be a valuable addi-
tion to the allergologist’s repertoire for desensitisation 
in case of patients suffering from adverse reactions sug-
gestive of an IgE-mediated allergy.
Abbreviation
DHR: drug hypersensitivity reaction.
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